Apyx Medical (APYX) Q4 2025 earnings review
AYON Launch Ignites Growth and Profitability
Apyx Medical has successfully engineered a turnaround. After quarters of shrinking sales, the September launch of the AYON Body Contouring System drove a massive 34.7% YoY revenue surge in Q4, reaching a record $19.2 million. More importantly, management held the line on operating expenses, creating massive operating leverage that pushed Adjusted EBITDA into positive territory ($0.7M) for the first time this year. While the legacy OEM business is in terminal decline, the core Surgical Aesthetics segment is accelerating rapidly, supported by the booming GLP-1 weight loss market.
🐂 Bull Case
The AYON system is completely transforming the top line. U.S. Surgical Aesthetics revenue exploded by nearly 50% in Q4, proving early customer demand is translating into rapid capital equipment deployment.
Apyx achieved positive Adjusted EBITDA of $0.7M in Q4, up from a $2.2M loss a year ago. The company demonstrated it can scale revenue without linearly scaling expenses.
🐻 Bear Case
The 510(k) clearance for AYON's power liposuction label expansion has been pushed from Q1 2026 to mid-2026, which could delay broader adoption among surgeons waiting for the complete feature set.
Despite a highly favorable mix shift toward the premium Surgical Aesthetics segment, Q4 gross margin actually contracted slightly YoY to 62.6% from 63.0%, exposing the rising cost of tariffs.
⚖️ Verdict: 🟢
Bullish. The AYON launch has structurally changed the company's trajectory from shrinking to hyper-growth in its core segment. The pivot to positive Adjusted EBITDA validates the business model, even if FDA delays and the fading OEM segment pose minor speed bumps.
Key Themes
AYON System Sparks Surgical Aesthetics Surge
The U.S. commercial launch of the AYON Body Contouring System in September fundamentally shifted the company's growth trajectory. Surgical Aesthetics revenue grew an accelerating 38.1% YoY in Q4 to $16.7M, completely reversing the sluggish single-digit growth seen early in the year. The all-in-one platform is capturing significant market share by integrating fat removal and tissue contraction.
GLP-1 Tailwind Fueling Structural Demand
Management continues to position Renuvion and AYON as the standard-of-care for patients experiencing skin laxity after massive weight loss from GLP-1 drugs. With an estimated 15 million+ users creating a burgeoning pipeline of patients needing body contouring, this macro trend provides a stable, multi-year driver for single-use handpiece consumption.
Operating Leverage Reversing Cash Burn
Apyx held Q4 operating expenses perfectly flat at $12.0M YoY while revenue surged by $4.9M. This extreme operating leverage reversed the company's profitability trend, turning a $2.2M Adjusted EBITDA loss into a $0.7M profit. The drastic reduction in cash burn extends their $31.7M cash runway comfortably through 2027.
Regulatory Delay for AYON Power Liposuction
Apyx submitted a 510(k) for AYON's label expansion to include power liposuction in October 2025. Previously expected in Q1 2026, management now anticipates clearance in mid-2026 following FDA discussions. This delay risks stalling sales momentum among surgeons who view power liposuction as a prerequisite for upgrading to the 'new gold standard' platform.
Gross Margin Contradicts Mix Benefit
Apyx's narrative is that shifting away from OEM toward high-margin domestic Surgical Aesthetics will boost profitability. However, despite U.S. Surgical Aesthetics jumping 50% in Q4, overall gross margin compressed from 63.0% to 62.6% YoY. Management explicitly blamed tariffs affecting H2 2025, revealing that supply chain costs are successfully eating away the mix-shift benefits.
OEM Segment in Terminal Decline
The OEM segment is officially being phased out as a meaningful contributor. Despite a strange 15.6% uptick in Q4 to $2.4M, FY25 OEM sales fell 20.9% to $7.5M. Guidance for FY26 models an accelerating collapse down to just $4.5M (-40% YoY). Apyx is now almost entirely dependent on Surgical Aesthetics execution.
Other KPIs
Reversing. A massive milestone for the company, turning profitable on an EBITDA basis compared to a $2.2M loss in 24Q4. This was achieved through a $4.9M revenue increase combined with zero YoY growth in operating expenses.
Stable. Cash balance ended the year completely flat versus the $31.7M reported at the end of 2024. Management believes this balance, paired with improving operating cash flow from the AYON rollout, is sufficient to fund the company through 2027.
Accelerating improvement. Net loss was cut by more than half compared to the $23.5 million loss posted in FY24. The Q4 net loss narrowed to just $1.3 million, down from $4.6 million in the prior year.
Guidance
Decelerating. The midpoint of $58.0M implies 9.8% YoY growth. While this represents a slowdown from the 34.7% hyper-growth seen in 25Q4, it reflects a blend of strong core growth fighting the severe drag of the collapsing OEM segment.
Stable. The midpoint implies 18.0% YoY growth from FY25's $45.3M. This assumes continued strong adoption of AYON and increased utilization of handpieces, carrying the momentum from the late-2025 launch through a full year.
Accelerating decline. Implies a brutal 40% YoY drop from FY25's $7.5M. The company is actively letting this segment fade to focus all commercial resources on its branded surgical portfolio.
Reversing. After successfully cutting operating expenses from $48.2M in FY24 down to $39.5M in FY25, management is planning to ramp spending back up by roughly 14%. This suggests heavy planned investments in AYON commercialization, marketing, and the delayed 510(k) process.
Key Questions
AYON 510(k) Delay Details
The power liposuction label expansion for AYON was pushed from Q1 to mid-2026 'following discussions with the FDA'. What specific concerns or requests for additional data did the FDA raise, and does this alter the anticipated R&D spend?
Tariff Mitigation Strategy
Despite incredible U.S. mix advantages, Q4 gross margins compressed YoY. With tariffs now visibly hurting the COGS line, what is the exact margin profile modeled in the FY26 guidance, and are price increases on AYON systems being considered?
Operating Expense Ramp
FY26 guidance calls for up to $45M in Opex, an increase of roughly $5.5M from FY25. How much of this is variable commission tied to higher AYON sales versus fixed investments in the new sales leadership structure?